Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091457 | 0.84 | MAPK1 (0.38) | POLBRAPGEF4EPHX2ALDH1A1KMT2A | |
| SCHEMBL4829904 | 0.78 | RAPGEF4 (0.37) | POLBRAPGEF4ALDH1A1KMT2AMAPT | |
| SCHEMBL5098088 | 0.75 | MAPK1 (0.39) | POLBALDH1A1 | |
| SCHEMBL4801414 | 0.72 | LDHA (0.38) | RAPGEF4ALDH1A1KDM4EMAPT | |
| SCHEMBL31749244 | 0.67 | ABL1 (0.41) | POLBALDH1A1MAPT | |
| SCHEMBL31749574 | 0.67 | PTPN11 (0.34) | POLBKDM4E | |
| SCHEMBL31749267 | 0.67 | MAPK1 (0.45) | — | |
| SCHEMBL15859430 | 0.67 | MEN1 (0.33) | KMT2A | |
| SCHEMBL1718745 | 0.64 | JAK2 (0.41) | KMT2A | |
| SCHEMBL4799601 | 0.64 | RAPGEF4 (0.38) | POLBRAPGEF4KDM4EKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-15 | — | — | US | disclosed |
| US-RE49500-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-25 | — | — | US | disclosed |
| EP-3943489-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | Vertex Pharmaceuticals Incorporated (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3608315-B1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | VERTEX PHARMA (US) | 2021-08-11 | — | — | EP | disclosed |
| US-RE48266-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3608315-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3305776-B1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | VERTEX PHARMA (US) | 2019-09-25 | — | — | EP | disclosed |
| US-RE47318-E1 | Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3305776-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2799434-B1 | Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds | VERTEX PHARMA (US) | 2017-08-02 | — | — | EP | disclosed |
| US-RE46097-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2799434-A1 | Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds | Vertex Pharmaceuticals Incorporated (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-1753738-B1 | Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds | VERTEX PHARMA (US) | 2014-07-09 | — | — | EP | disclosed |
| US-7354939-B2 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1753738-A1 | PYRROLE COMPOUNDS AS INIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | Vertex Pharmaceuticals Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060106069-A1 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-05-18 | — | — | US | disclosed |
| WO-2005113541-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | MAPK1, MAP3K1, MAP3K20 | POLB 1198/4885PHGDH 632/4885RAPGEF4 704/4885 |
| US-20060106069-A1 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | MAP3K1, MAP4K2, MAP3K4 | POLB 1354/4885PHGDH 893/4885RAPGEF4 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.